beyond wall initi coverag innov cell therapi platform
messag initi coverag biotechnolog stock view develop
innov next-gener cell therapi platform approv adopt cell therapi kymriah nv yescarta
demonstr signific clinic activ valid class therapeut said first gener individu
treatment face signific commerci challeng initi product launch disappoint eye mani investor
crop next gener cell therapi compani util novel genet engin technolog develop allogen off-the-
shelf cellular therapi could potenti overcom limit face individu autolog therapi among
rate buy neutral
next-gener cell therapi platform repres emerg innov categori among compani focus
oncolog new cellular cancer therapi car-t cell treatment hold promis potenti revolution treatment
paradigm oncolog approv adopt cell therapi kymriah nv yescarta well clinic stage asset
liso-cel celg blue/celg demonstr signific clinic activ far exceed exist standard
multipl myeloma mm said first gener autolog product also face sever challeng
led disappoint commerci product launch eye investor potenti limit first gener car-t therapi
includ high cost access hurdl complex individu treatment logist treatment-associ safeti risk crop
next gener cell therapi compani util novel genet engin technolog attempt overcom limit face
autolog therapi develop allogen off-the-shelf cellular therapi view potenti overcom
key issu face first gener product achiev reliabl low cost manufactur off-the-shelf product
avail potenti improv efficacy/safeti significantli broader rang potenti product applic note
initi coverag innov early-stag next-gen cell therapi compani focus develop new class off-
initi coverag biotechnolog stock view develop innov
next-gener cell therapi platform leadership proven manag team view front-runn
potenti bring first off-the-shelf car-t therapi market think could potenti leapfrog peer util induc
pluripot stem cell ipsc platform develop engin cancer cell immunotherapi entir dish process dissimilar
produc monoclon antibodi develop highli differenti cell therapi platform base genet
engin red blood cell potenti new class therapeut uniqu properti applic span rare diseas cancer
autoimmun condit rate buy neutral still earli develop stage think
signific upsid could potenti gener success still trade enterpris valu
potenti catalyst approach believ could increment de-risk respect technolog platform
overal posit leadership pipelin strategi believ lot upsid alreadi reflect current ev
visibl potenti catalyst year limit
page analyst certif import disclosur
buy pt first name could potenti leapfrog competitor appli ipsc
platform develop engin off-the-shelf cancer immunotherapi dish still earli stage poc data emerg
although still earli stage believ fate induc pluripot stem cell ipsc platform could potenti improv upon sever
shortcom first also second gener cellular cancer immunotherapi broad set potenti applic across
oncolog immunolog therapeut area signific long-term upsid potenti unlik competitor gener self-
renew nk car-t cell line reproduc manufactur process akin monoclon antibodi given
earli develop stage heavili probability-adjust disclos pipelin program initi poc clinic data fate ink-cel
program could potenti gener year-end ind submiss first car-t cell program
year repres key mileston view also plan expand clinic pipelin near term icar-nk program
ind year two icar-t program partnership co pt
rubiu buy pt blood magic uniqu red cell therapeut platform key proof-of-concept data
develop highli differenti cell therapi platform base genet engin red blood cell
potenti new class therapeut uniqu properti rang potenti applic extrem broad rang rare
genet diseas cancer autoimmun diseas still earli stage develop beachhead pipelin strategi
think potenti enabl increment de-risk entir group relat product applic posit proof-of-concept poc
data respect lead product candid emerg first clinic data rubi lead rare diseas program pku
guid ind submiss first oncolog program guid guid ind file though end
total rapidli broaden clinic stage pipelin valu creation opportun longer term pt
allogen neutral breaker chain potenti front-runn bring off-the-shelf car-t market
believ well-posit potenti develop one first allogen off-the-shelf car-t cell therapi pursu valid
target bcma allo high-profil manag team histori success track record gener sharehold
return categori well sever year prior invest platform could significantli reduc develop risk
view overal posit allo platform pipelin strategi priorit build superior manufactur capabl
pursu fast-follow product approach follow expans solid tumor believ lot alreadi reflect
current valuat visibl potenti catalyst limit guid releas initi phase result
program lymphoma eu partner servier may provid updat phase studi
year-end ind submiss bcma-target plan
page analyst certif import disclosur
initi coverag
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
page analyst certif import disclosur
initi emerg biotechnolog stock focu next-
compani focus oncolog
approv adopt cell therapi kymriah nv yescarta demonstr signific clinic activ
valid class therapeut
said first gener individu treatment face signific commerci challeng initi product
launch disappoint eye mani investor
crop next gener cell therapi compani util novel genet engin technolog develop allogen off-
the-shelf cellular therapi could potenti overcom limit face individu autolog
initi coverag neutral buy
leadership proven manag team view front-runn potenti bring first off-the-shelf
car-t therapi market
think could potenti leapfrog peer util induc pluripot stem cell ipsc platform develop
engin cancer cell immunotherapi entir dish process dissimilar produc monoclon antibodi
develop highli differenti cell therapi platform base genet engin red blood cell
potenti new class therapeut uniqu properti applic span rare diseas cancer autoimmun
still trade enterpris valu potenti catalyst approach
believ could increment de-risk respect technolog platform overal posit leadership
pipelin strategi believ lot upsid alreadi reflect current ev visibl potenti catalyst
year limit
page analyst certif import disclosur
initi coverag emerg biotechnolog stock focu
next-gener cell therapi platform
highli differenti induc pluripot stem cell ipsc -base platform could potenti enabl gener off-the-
shelf nk car-t cell line reproduc manufactur process akin monoclon antibodi
develop proprietari partner ophli pipelin around nk cell t-cell disclos
initi poc clinic data fate ink-cel program could potenti gener year-end ind
submiss first car-t cell program year repres key mileston view
highli differenti cell therapi platform base genet engin red blood cell potenti new class
therapeut uniqu properti
beachhead pipelin strategi could potenti de-risk broad set opportun across rare genet diseas oncolog
first clinic data rubi lead rare diseas program pku guid ind submiss first
oncolog program guid guid ind file end total rapidli broaden
clinic stage pipelin valu creation opportun longer term
spun believ well-posit potenti develop one first allogen off-the-shelf car-t
fast-follow product approach follow lead car-t program target bcma
guid releas initi phase result program lymphoma eu partner servier may
provid updat phase studi year-end ind submiss bcma-target
plan
page analyst certif import disclosur
themat coverag continu focu sever innov area
within oncolog therapeut categori
wide valid class oral small molecule-bas drug tki believ re-emerg context precis
medicin includ biomark select select next gener tki dramat increas sinc first agent
enter market decad ago result side effect decreas durabl respons increas
valid class antibody-bas agent ink cytotox payload gen agent success
believ categori re-emerg sever pivot dataset regulatori decis expect
next-gener antibodi platform could potenti build insight gain recent year key advanc
inhibitor car-t disappoint immun agonist made immuno-oncolog
expect enthusiasm cancer immunotherapi remain high given valid via agent car-t
approv well substanti market potenti first gener individu treatment face signific commerci
challeng view next-gener cell therapi compani util novel genet engin technolog develop
allogen off-the-shelf cellular therapi could potenti overcom limit face individu
page analyst certif import disclosur
page analyst certif import disclosur
page analyst certif import disclosur
first gener car-t cell therapi potenti revolution treatment standard across
approv adopt cell therapi kymriah nv yescarta well clinic stage
asset liso-cel celg blue/celg demonstr signific activ far
exceed exist standard care across relapsed-refractori hematolog cancer includ diffus larg
 cell lymphoma dlbcl acut lymphocyt leukemia multipl myeloma mm
howev signific room improv current technolog exist view
potenti limit gen product includ cost/access high product cost singl dose limit
engin heterogen drug product safeti profil high rate cytokin releas syndrom
gener cell therapi develop util novel technolog attempt overcom
limit face autolog therapi
manufactured/engin red blood cell-bas off-the-shelf therapeut span broad rang
page analyst certif import disclosur
commerci first two car-t begin
innov cycl view despit year prior academ research
fusion protein compos extracellular
portion usual deriv antibodi
intracellular signal modul deriv cell signal
possess costimulatori endodomain
fuse recent consist
two costimulatori domain link
car-t type treatment patient cell
type immun system cell collect engin
amplifi lab infus back patient
attack cancer cell lab gene chimer antigen
receptor could recogn specif cancer cell
introduc cell henc name car-t
propos
concept car-t
improv design
ad
preclin studi
base recent
aug fda approv
car-t kymriah b-cell
oct fda approv
car-t yescarta dlbcl
may fda approv
kymriah dlbcl
page analyst certif import disclosur
car-t treatment significantli exceed efficaci bar hematolog
cancer hold potenti revolution treatment paradigm
cell therapi heftili clear efficaci bar set exist standard care pre-treat relaps patient across
lymphoma leukemia myeloma therapeut class cell therapi yield deep durabl respons
cell therapi yield deep durabl respons long-term follow-up includ patient treat
yescarta still respons median month relapse-fre probabl month patient treat kymriah
cell therapi approv mm yet graph show clinic data long term follow show mdor post-kymriah least month dlbcl least month soc dlbcl clolar darzalex mm
guggenheim secur llc analysi drug approv drug
page analyst certif import disclosur
howev sever challeng arisen autolog therapi
autolog car-t therapi encount manufactur
failur enrol patient clinic set
meanwhil patient withdrew studi
progressed/di wait manufactur product
clinic set median vein-to-vein time leukapheresi
infus rang week
cite manufactur time clinic set
progressed/ die
patient product
patient treat
product spec
day rang day median time
median time leukapheresi product deliveri
leukapheresi infus day rang day
median time leukapheresi cryopreserv
kymriah infus day rang day
median vein-to-vein time phase pilot studi among
patient day rang day
exist car-t therapi shown high rate toxic
includ cytokin releas syndrom neurotox
approv car-t therapi price dlbcl
reimburs far acquisit cost medicar
within medicar channel car-t reimburs
accord asbmt ms-drg car-t
classifi autolog bone marrow transplant t-cell
immunotherapi payment rate
limit lesser excess
cost product car-t cap
thu center reimburs maximum still
acquisit cost car-t therapi
inclus subsequ post-treat stay cost
note kymriah price
guggenheim secur llc nv compani present american societi blood marrow transplant propos car-t coverag payment option letter
page analyst certif import disclosur
result challeng commerci autolog car-t therapi
complex requir success implement key factor
manufactur approv car-t therapi build commerci infrastructur necessari
support novel therapi includ complex logist prove challeng least initi
factor requir car-t commerci
reliabl manufactur
financi aspect center
fda guidanc car-t therapi
list price plu
highlight need uniform
consist spec across product
despit autolog natur
clinic must certifi
inpati care quickli greatli
risk evalu mitig
rem therapi
exceed reimburs amount
result net loss center
manufactur product need
consist reliabl thu must
close monitor regul
time manufactur
car-t elig patient relaps
aggress form b-cell lymphoma
stall treatment wait
weeks/ month treatment becom
physician work rems-certifi car-t
treatment center describ rem
certif process long extens
result uncommon site
get certifi treatment option
oppos indic
accord physician spoke
physician spoke explain
priorit car-t treatment option low
failur rate increas reliabl speed
next therapi
physician told us need pitch
rational need
hospit manag team
need differenti clinic profil warrant
reimburs one key factor
given average age dlbcl diagnosi
product later line
set like r/r dlbcl
patient insur medicar
car-t therapi still result larg
net loss treatment center
reimburs drg
enough simpli
need econom
feasibl treatment center
yield net loss center
addit inpati stay requir
page analyst certif import disclosur
kymriah novn yescarta potenti case studi
commerci launch new therapeut class complex product
despit car-t therapi approv broader label
span dlbcl kymriah slower commerci
launch rel yescarta think part could potenti
attribut lower physician confid nv manufactur process
base check cost/reimbursement/access hurdl base
feedback lead us center
seen variabl product specif
manufactur cell viabl
spec theyr level
yescarta faster initi launch vs kymriah potenti due
effect rems/sit qualif accord physician spoke
investor concern mount howev us sale growth slow
middl adopt late adopt group
realli tri figur make work within institut
take time go take time get
growth rate needi confid get better
medic practic get better get better manag
side effect around importantli futur get
drg code grow import busi gilead
street consensu estim yescarta reach kymriah reach net sale
guggenheim secur llc evaluatepharma consensu estim nv earn call transcript
page analyst certif import disclosur
sever potenti area improv current gener cellular
r/r patient particularli hematolog malign often lymphopen
diseas and/or previou chemotherapi also may theoret possibl t-cell
enhanc phenotyp
cancer patient impaired/ dysfunct rel healthi individu
characterist start materi
complex multi-step logist individu autolog car-t take week
ready-to-us batch pre-
averag patient could requir bridg chemotherapi progress
gener manufactur failur machineri malfunct drug product outsid
ready-to-us batch pre-
t-cell harvest alway yield suffici lymphocyt number support
specif still occur clinic set
contamin
patient r/r diseas frequent leukemia cell circul blood
harvest incident leukapheresi process case
patient unintent treat contamin kymriah
enhanc phenotyp
characterist start materi
cost manufactur cell therapi remain high given highli complic logist
ineffici scale sinc drug product individu made patient
estim cog repres net sale initi assum decreas time
increas scalabl elimin
ratio drug product patient
manufactur scale howev could cost-prohibit
drug product made individu patient cell imposs
autolog cell therapi yield complet standard product exampl patient
kymriah pivot juliet studi receiv median dose cell rang
 patient yescarta pivot trial receiv median dose
cell rang
creat homogen product
donor cell wide use
possibl cell could vari due random integr transgen doubl strand
break dna genet transloc off-target edit also due imperfect success
platform edit singl cell
rate exist edit platform cell engin
expand
current autolog cellular therapi develop process case yield
dose one singl treatment patient per manufactur run
increas scalabl elimin
ratio drug product patient
current car-t product afflict sub-optimal safeti profil often high rate
cytokine-rel toxic cytokin releas syndrom neurotox
develop car-t switch
potenti solut major limit face autolog cell therapi center around use healthi donor cell
start materi scale manufactur ready-to-us pre-prepar drug product
page analyst certif import disclosur
industry-wid compani investig novel approach improv
sever manufactur evalu next gener cellular therapi potenti resolv hurdl
face current avail cellular therapi attempt use better potenti phenotyp enhanc start materi
manufactur develop allogen therapi deriv healthi donor cell batch use mani
patient oppos patient autolog therapi compani take step develop
therapi gener induc pluripot stem cell differenti cell interest batch
theoret unlimit use patient
genet engin
genet modifi patient
lymphocyt express specif cancer-
t-cell receptor tcr
lymphocyt enabl allogen transfer
express specif cancer-recogn
chimer antigen receptor t-
singl stem cell genet engin
in-vitro carri therapeut protein
target receptor differenti
self-renew cell-lin target cell
limit number dose
guggenheim secur llc pictur compani present natur sangamo
page analyst certif import disclosur
autolog cell therapi gener becom increas
focu small larg biopharma compani alik
select first gener cell therapi compani
guggenheim secur llc factset
page analyst certif import disclosur
compani disclos effort focus next gener
cellular therapi cancer/immunology-rel indic
select gener cell therapi compani
khlori leap bayer
allogen pluripot stem cell crispr
autolog ipsc macular degener
anti-canc vaccin base human ipsc
therapeut base genet engin
therapeut base hypoton load
therapeut base hypoton load
therapeut engin surfac bind
therapeut engin surfac bind
guggenheim secur llc factset next gener cell therapi program lead candid
page analyst certif import disclosur
compani profil first name
page analyst certif import disclosur
rate buy develop one
differenti diversifi cellular therapi platform
although still earli stage believ fate induc pluripot
shortcom gen cellular cancer immunotherapi
broad set potenti applic across oncolog immunolog
therapeut area signific long-term upsid potenti given
earli develop stage heavili probability-adjust disclos
pipelin program initi poc clinic data fate
nk-cell program could potenti gener year-end
ind submiss first car-t cell program year repres
key mileston view valu pt
potenti develop risk ipsc-deriv product
probability-of-success fate adopt nk cell therapi
probability-of-success fate adopt car-t cell
potenti degre differenti increasingli crowd
opportunity/valu fate legaci product includ
protmun
enrol complet phase ii protect studi
clinic updat monotherapi aml
ovarian cancer combin mab solid
initi clinic data solid tumor
initi clinic data heme malign
ind file
ind submiss
estim shown consensu estim chart slide overal market perform
page analyst certif import disclosur
fate develop pipelin primarili focus oncolog explor
nk cell t-cell therapi
emerg compani platform built upon induc pluripot stem cell ipsc -deriv
program treatment cancer autoimmun diseas led next-gener cell therapi pioneer effort first-
ever ind clear ipsc-deriv therapi well first ever ind clear genet engin ipsc-deriv therapi
fate advanc asset date nk-cell base immunotherapi intend synerg exist monoclon
antibodi hematolog solid tumor also enter collabor co ophli
develop potenti commerci off-the-shelf car-t asset although target yet disclos
plan move manufactur hous launch gmp manufactur headquart management guid toward
complet first in-hous clinic run year-end
updat data aml
ovarian mono
prevent acut gvhd
page analyst certif import disclosur
bull innov differenti cell therapi
platform could potenti leapfrog next-gen car-t
immunotherapi platform could potenti leapfrog
rich set product develop opportun span
cell nk cell
pipelin near potenti de-risk catalyst later year
next
pipelin still predominantli wholli own gener poc
data potenti enhanc strateg valu increas
percept option
bear high-risk given earli stage limit clinic
proof-of-concept date
signific develop regulatori risk still exist around
fate ipsc platform given earli stage lack clear
nk cell-bas therapi proven paradigm-
shift date
competitor potenti rais bar
develop highli differenti platform
could potenti leapfrog next-gen cell
enabl gener cellular anti-canc therapi deriv
genet engin clonal cell line
manufactur compar way monoclon antibodi
therapi potenti resolv mani potenti logist
commerci limit current face autolog cellular
proof-of-concept trial updat guid year could
follow ind clearanc management guid present
first clinic data two ink-cel program solid
tumor hematolog malign year-end
sourc signific upsid longer term although earlier
stage anticip fate ipsc car-t pipelin becom
signific valu driver long-term support clinic
commerci preced via yescarta kymriah
valuat upsid potenti pt higher
current price
page analyst certif import disclosur
gs assumpt upside/downsid scenario
 regulatori commerci setback
potenti emerg new competitor
po protmun approv gvhd
po
po
valu
dilut financ beyond assum
concept nk cell platform
assum non-car asset pure nk cell therapi
unsuccess clinic po asset
goe
could success po
assum asset nk cell -t cell
page analyst certif import disclosur
fate valu proposit almost entir driven differenti induc
although two gener asset alreadi clinic protmun ipsc-
deriv cellular therapi drive valu longer term opinion ipsc-deriv platform begin
healthi uncompromis chemotherapy-nav immun cell ii requir singl engin event iii yield
homogen drug product iv improv cost effect margin demonstr scalabl vi give option
multipl dose vii tremend option given ipsc differenti distinct cell type
leader ipsc-deriv cell therapi view pioneer way clear first ipsc-deriv therapi
ind earlier year date minim competitor exist ipsc landscap includ adap buy evotec evtci
fate ipsc platform protect broad set patent includ issu patent well pend
patent applic accord manag
guggenheim secur llc compani present pictur nih
page analyst certif import disclosur
date develop progress distinct nk cell program
clinic trial set preced ipsc-deriv therapi ind clearanc
compris adapt memori nk cell
form proprietari combin
pharmacolog modul consist
induc format adapt
memori nk cell substanti quantiti
nk cell immunotherapi deriv
singl ipsc select
clonal expand
nk cell immunotherapi deriv
singl ipsc engin express high-
receptor design enhanc
receptor bind affin igg
antibodi prevent shed
receptor post-nk cell activ
hematolog solid tumor
ind allow fda clinic trial
initi data expect
ind allow fda clinic trial
plan data expect
monotherapi combin
monotherapi combin
page analyst certif import disclosur
util nk cell foundat advanc cell therapi
despit histor limitations/underwhelm dataset clinic set
natur killer nk cell theoret well-suit adopt cancer immunotherapi
nk cell part innat immun system larg granular lymphocyt inherent/ natur abil
recogn kill foreign infect and/or malign cell well modul aspect immun system via
chemokin cytokin secret nk cell anti-tumor activ unlik t-cell depend antigen recognit
requir prime prior sensit
nk cell abil kill virus-infect cancer cell sever distinct way directli via recognit stress
cell indirectli via tumor cell apoptosis-induc ligand express mediat antibody-depend cellular cytotox
recruit adapt immun cell via secret ifn-gamma variou cytokin
activ adapt
immun system
stress cell independ
direct kill target cell
granul releas
nk cell therapi date mix overal underwhelm result particularli non-myeloid malign
greatest success observ aml clinic result quickli favor allogen autolog nk cell therapi
given graft vs leukemia effect observ allo-react nk cell although well vet nk cell infus safe
elicit gvhd studi evalu variou diseas diseas state nk cell number consist shown lack
nk cell expans persist well weak efficaci among refractori patient howev among aml patient nk cell
adopt transfer demonstr compel result depth durabl respons use consolid therapi
aim resolv limit seen among predecessor given focu enhanc donor nk cell
either via use function distinct adapt memori subset nk cell engin optim nk cell
guggenheim secur llc graphic adapt compani present
page analyst certif import disclosur
donor-deriv gener nk-cell therapi could
nk cell immunotherapi consist adapt memori nk cell function distinct subset nk cell
shown preclin studi enhanc effector function long-term persist greater resist immun
checkpoint pathway adapt memori nk cell also correl reduc relaps risk superior post-hct
collabor univers minnesota develop pharmacolog modul combin
contain cytokin small molecul togeth induc format adapt memori nk cell use program
cell healthi donor peripher blood feeder-fre ex-vivo manufactur process
role within broader pipelin remain obscur given overlap clinic footprint
lead ipsc-deriv asset like substanti commerci product opinion howev
benefici sever reason provid team experi design execut clinic trial
increas confid fate pipelin develop importantli valid fate platform nk cell-bas therapi
compos matur nk cell
pre-clin data show anti-tumor activ alon
combin monoclon antibodi mab
page analyst certif import disclosur
anti-tumor activ seen patient treat across
on-going ph trial expect result appear strongest aml
evalu monotherapi combin monoclon antibodi mab across phase i/ii
clinic trial program voyag aml apollo ovarian cancer dimens variou solid tumor
phase clinic updat provid
blast
pif decitabin
refract clo/cytarabin detect
pif
pif
day
sd w/ decreas
what next confirm intend complet initi phase trial continu gain
knowledg clinic experi benefit pipelin broadli given clinic overlap sever ipsc asset
path forward remain vagu time data updat studi expect throughout
guggenheim secur llc compani present
page analyst certif import disclosur
believ main valu driver ipsc-deriv cell
therapi franchis current encompass disclos asset
fate induc pluripot stem cell ipsc technolog highli differenti produc gener cellular therapi
next-next gener cellular therapi technolog allow select singl ipsc expand
differenti one distinct cell type includ nk cell t-cell myeloid-deriv suppressor cell
ipsc-deriv product could potenti solv numer challeng face autolog cell immunotherapi given
abil gener cost-effect homogen multi-dos product expand base phenotyp selected-for ipsc
repres scalabl cellular therapi franchis yet establish autolog car-t product
fate reprogram donor cell ipsc cell allow differenti distinct cell type
differenti
first obtain normal human donor cell
fibroblast hematopoiet cell conduct
reprogram donor cell induc
pluripot use proprietari transgen
integration-fre footprint-fre method addit
cell engin stage applic
singl ipsc isol select
singl ipsc clonal expand produc clonal
ipsc line expand differenti
cell expand differenti
produc cell popul interest
page analyst certif import disclosur
ipsc-deriv cell line potenti enabl gener homogen off-the-
shelf cell product follow singl engin step
dose cellular therapi sever million cell liquid tumor sever billion cell solid tumor current gene
edit technolog aim engin cell individu result heterogen mix engin non-engin cell
product among engin locat edit vari
ipsc-deriv cell line start singl cell singl engin event necessari although could
perform enhanc product singl cell confirm accur gener expand
million cellular clone provid clear benefit allogen donor t-cell therapi creation requir gene engin
cell level data date show technolog yet success rate
gain experi navig ipsc-deriv cell ind submiss regulatori bodi submit
landmark ind applic first file use master ipsc line renew sourc produc off-the-
shelf cell product manag state
belief part time period took get clear file juli clear late novemb
big piec familiar fda platform natur reprogram cell select clone creat
master cell bank qualifi master cell bank ultim differenti product candid ceo
next ipsc-deriv ind subsequ allow day
page analyst certif import disclosur
first ipsc-deriv nk cell product obtain fda-allow ind
could play key role de-risk fate ipsc-deriv therapi platform
off-the-shelf ipsc-deriv nk cell therapi current evalu treatment solid tumor
monotherapi combin checkpoint inhibitor accord combin rational base recent
analysi suggest delet loss heterozygos common mechan resist
checkpoint inhibitor cpi studi show patient progress diseas post-cpi treatment express
defect addit loss heterozygos enrich non-respond compar respond
associ poor os essenti compon mhc class molecul critic antigen present
defect could overcom use allogen nk cell given abil directli kill cell mhc class downregul
preclin data suggest synergi among cpi t-cell present result vitro tumor spheroid
model show enhanc target tumor cell elimin activ cell antibodi compar
alon activ t-cell alon activ t-cell antibodi
first safeti hurdl clear clinic set follow toler safeti profil among patient dose first dose
level dose-limit toxic seriou advers event report date dose cohort open enrol
preclin data show increas t-cell tumor infiltr increas cytotox
preclin data present
what next follow ind allow nov first patient treat feb phase
dose escal trial continu enrol monotherapi arm among candid salvag therapi patient
failed/progress cpi combin arm cpi patient failed/progress initi data expect co
guggenheim secur llc compani present poster
page analyst certif import disclosur
engin ipsc-deriv nk cell product obtain fda-
allow ind enter clinic sometim year
layer addit complex technolog engin cell product engin
element ensur express high affin non-cleav fc receptor recal nk cell express activ
receptor bind fc portion igg antibodi transmit immun respons signal activ nk
cell abl lyse antibody-co target cell secret cytokin interferon gamma recruit potenti adapt
immun cell cell adcc mechan proven critic treatment wide rang human tumor type
engin prevent shed non-cleav upon nk cell activ
nk cell play major role anti-tumor efficaci certain tumor-antigen target monoclon antibodi anti-tumor efficaci
sever approv mab rituxan herceptin shown nk-cell depend also studi shown anti-
tumor efficaci significantli enhanc patient singl nucleotid polymorph result express high affin
isoform increas strength bind igg antibodi human homozyg allel
preclin data show synergist enhanc efficaci mice treat mab rituxan rhhbi
preclin data updat previou poster present
what next follow ind allow grant fda februari evalu open-label
repeat-dos multi-cycl dose escal phase studi among cohort patient r/r hematolog malign aml
monotherapi nhl combin rituxan mm combin elotuzumab data expect
page analyst certif import disclosur
rapidli expand ipsc-deriv cellular therapi platform
includ nk cell car-t cell-deriv asset
rapidli expand ipsc-deriv cellular therapi platform new asset alreadi underway develop
shelf nk cell product candid incorpor novel specif design enhanc
increas nk cell signal call contain transmembran domain co-stimulatori domain
signal domain mediat strong antigen-specif nk cell signal vitro ind submiss plan
shelf nk cell product candid use antibodi darzalex mm recal
highli express mm cell also activ nk cell reason treatment lead nk cell fratricid
could decreas efficaci adcc-medi target mm cell elimin also nk cell function shown
diminish even absent mm patient reduc efficaci
shelf ipsc-deriv car-t product multi-year partnership memori sloan ketter cancer
center also express high affin non-cleav receptor increas receptor bind affin
igg antibodi block shed receptor express surfac activ nk cell
anti-bcma name tbd option agreement max delbrck center molecular medicin human anti-bcma
could use either nk -t cell
what next addit ipsc-deriv product ind need asset plan move human test
clinic trial guid toward clear ind submit ind year
page analyst certif import disclosur
could help de-risk expans immunolog inflamm
consist myeloid-deriv suppressor cell mdsc natur occur immun regulatori cell popul abl
suppress t-cell immun cell type allow regul physiolog pathophysiolog condit mdsc
often found tumor microenviron inhibit t-cell activ prolifer
preclin data confirm t-cell suppress ipsc-
deriv mdsc term activ prolifer
plan exploit t-cell suppress capabl mdsc order
suppress auto-react cell caus tissu destruct
result occur across mani autoimmun diseas
yet disclos lead indic
state see therapeut potenti graft-versus-host diseas
gvhd multipl sclerosi ms ulcer coliti uc among
mdsc mechan action
success platform could substanti differenti given vast number patient form
autoimmun diseas million fate immuno-regulatori franchis could big cell typic rare
healthi donor found ampl number patient tumor differenti abil potenti produc larg
number cell use ipsc platform
what next yet submit ind propos lead indication/ clinic path forward
expect fate focu remain lead ipsc-deriv candid accru preclin data
page analyst certif import disclosur
remain far ahead ipsc competit first
compani current clinic ipsc-deriv asset
leap bayer
model
ipsc platform
octob enter collabor licens agreement
univers cell creat gene-edit ip cell line
decemb enter collabor celgen may elect
screen compound proprietari celmod librari use
collabor reprocel
treat
demyelin degen diseas magiq
joint ventur contribut patent
technolog deriv manufactur glial-restrict progenitor grp
cell tissu sourc includ ipsc
april leap bayer invest arm global
scienc co bayer bayn khlori bioscienc announc
join forc develop novel
vaccin base human induc pluripot stem cell ipsc
april bluerock announc
research collabor cross-licens agreement combin
respect genom edit cell therapi technolog creat
allogen pluripot stem cell psc part cross-licens
agreement bluerock gain non-exclus right
crispr technolog intellectu properti
gain non-exclus right bluerock ipsc cell differenti
technolog intellectu properti respect field
transplant autolog induc pluripot stem
cell ipsc deriv retin pigment epithelium rpe cell sheet
treatment macular degener develop ex-u
present preclin data hipsc platform asgct
built industri ipsc infrastructur enabl research
collabor licens agreement harvard univers
demyelin
page analyst certif import disclosur
protmun fate asset furthest along clinic develop like
minim impact fate longer term valu proposit
protmun next gener allogen graft demonstr posit earli clinic data suggest
potenti reduc sever gvhd maintain strong graft-vs-leukemia activ
protmun current evalu phase ii stage phase i/ii protect patient hematolog malign
protmun appear substanti reduc incid gvhd day patient agvhd-fre
par establish incid gvhd among allogen transplant patient howev sampl size small
protmun howev appear reduc sever gvhd case acut gvhd resolv promptli follow
standard care steroid appear benefit given rate steroid-refractori among agvhd patient
protmun appear reduc efficaci transplant patient aliv relapse-fre day
aliv relapse-fre day
what next protmun per manag guidanc phase ii protect studi expect complet enrol
top-line data primari secondari endpoint expect read
page analyst certif import disclosur
enter sever collabor past year
whitehead institut
center
univers
univers california
tcr
licens portfolio whitehead institut patent famili relat
reprogram somat cell pluripot state well method make
cell suscept reprogram agreement continu
last licens patent expir ii institut termin agreement
default perform challeng patent right
enter research collabor univers led jeffrey miller
deputi director mason cancer center well clinic
translat scienc institut univers minnesota collabor
origin focus develop adapt memori nk cell cancer
immunotherapi expand includ develop
ipsc-deriv target nk cell cancer immunotherapi
enter research collabor memori sloan ketter
cancer center led michel sadelain ph director center cell
engin stephen barbara friedman chair well recogn
founder t-cell therapi collabor focus support
develop engin ipsc-deriv car-t cell immunotherapi ft-
enter research collabor ucsd led kaufman
ph professor medicin divis regen medicin director
cell therapi ucsd school medicin collabor focus ipsc-
enter research collabor licens agreement juno
celg identifi small molecul modul improv t-cell function
genet engin t-cell tcr immunotherapi collabor
respons identifi small molecul modul juno
respons develop commerci car-t tcr immuno-
therapi incorpor said modul
page analyst certif import disclosur
page analyst certif import disclosur
incom statement sales- collabor total cogs- total cost oper interest interest incom incom tax- net comprehens incom comprehens dilut ep per share outstand balanc sheet cf short-term short term revenu build
page analyst certif import disclosur
page analyst certif import disclosur
rate buy develop highli
differenti cell therapi platform base genet
engin red blood cell potenti new class therapeut
uniqu properti rang potenti applic
extrem broad rang rare genet diseas cancer
autoimmun diseas still earli stage
develop beachhead pipelin strategi think potenti
enabl increment de-risk entir group relat product
applic posit poc data respect lead product
candid emerg first clinic data rubi lead rare
diseas program pku guid ind
submiss first oncolog program guid
year pt
probability-of-success rubi ert enzym
replac therapi program includ
probability-of-success rubi oncolog program
potenti differenti tradit antibody-bas
probability-of-success rubi antigen present cell
applic autoimmun diseas
potenti manufactur risk includ scale cost
potenti safeti risk given new form therapi
phase clinic result pku
present addit preclin data cancer
ind file
phase i/ii trial homocystinuria
estim shown consensu estim chart slide overal market perform
page analyst certif import disclosur
emerg biotechnolog compani focus develop red blood cell-bas therapeut proprietari
platform enabl larg scale product therapeut activ red blood cell rbc gener donor-deriv
hematopoiet stem cell genet modifi carri therapeut protein interest intern cell surfac rubi
pipelin strategi focus three therapeut area rare genet diseas oncolog autoimmun diseas
number earli stage asset develop lead product candid phase trial treatment
phenylketonuria pku rubi lead cancer asset target ind guid earli
autoimmun diseas product candid discoveri stage guid total ind file
page analyst certif import disclosur
differenti therapeut fulfil unmet medic need
across broad rang diseas
first-in-class therapeut platform high barrier entri
could potenti gener new class therapeut
broad set product develop opportun
span rare diseas oncolog autoimmun diseas
pipelin strategi design stepwis de-risk whole group
potenti therapeut applic beachhead strategi
includ clinic valid new treatment modal
pipelin near potenti de-risk catalyst later year
next
pipelin still wholli own gener poc data
potenti enhanc strateg valu increas
percept option
modal limit clinic proof-of-concept date
signific develop regulatori risk still exist around
rubi red platform given earli stage lack clear
manufactur risk cost may underestim given
rubi product first-in-class
develop potenti disrupt technolog
platform could address mani unmet medic need
rubi platform could potenti enabl gener broad
rang differenti cellular therapi deriv
genet engin red blood cell take advantag
uniqu featur make prime drug-deliveri
vehicl manufactur transfer lack genet
de-risk entir therapeut categori leverag
red platform develop drug candid three therapeut
field rare enzym defici cancer autoimmun
diseas potenti clinic success one program within
therapeut categori could view potenti de-
risk entir group potenti diseas market similar
first clinic poc trial result guid could
follow recent ind accept guid
present first phase clinic result
program phenylketonuria pku could
potenti provid import insight safety/toler
rubi product well address key efficaci question
deep pipelin longer term guid file ind
though end span therapeut
page analyst certif import disclosur
per dcf year expir
market exclus last clinic program
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
po four rare diseas program
po three cancer program
po two autoimmun program
posit proof-of-concept data ph ib trial
pku po rare
posit pre-clin data cancer program
ind po cancer
disappoint data ph ib trial pku
po rare diseas program po
cancer program
po rare diseas program cancer program autoimmun program
po rare diseas program cancer program autoimmun program
page analyst certif import disclosur
rubi proprietari red platform novel approach gener
rubiu red platform origin flagship lab flagship pioneer also incub biotech compani includ
rbc therapeut
cell univers
page analyst certif import disclosur
rubi initi therapeut area focu includ rare enzym defici
cancer autoimmun diseas
engin express
transgen enzym within cell
therapi enzym degrad
clear pathogen metabolit
enzym howev shield
red blood cell neutral
immun system thu may
significantli prolong half-lif
better toler accord
engin express cell
surfac protein involv immuno-
cell surfac ligand rct
natur conform compar
nake protein antibodi
recombin cytokin could
hypothet induc potent cell-
cell interact larger therapeut
window due favor safeti
profil accord
engin express
process antigen-express
rct special cell liver
may induc toler improv
symptom autoimmun diseas
page analyst certif import disclosur
beachhead pipelin strategi success one singl asset could potenti
reduc develop risk asset within categori
factor success
traffick affect tissu
activ degrad pathogen
factor success
traffick affect tissu
factor success
page analyst certif import disclosur
phenylketonuria pku rare diseas signific unmet need
pku rare diseas deriv ineffect pah
accumul phenylalanin phe
current avail treatment option
moder effect safeti issu
phenylketonuria pku diseas caus defici
enzym phenylalanin hydroxylas pah need break
dietari phenylalanin phe high level phe caus
motor dysfunct psychiatr disord irrevers brain
us preval incid rate
sever diseas determin blood phe level
moder pku phe level mol/l
classic moder pku patient account
pku patient us
restrict dietari phe intak
current mainstay pku therapi meat dairi nut egg
etc difficult compli patient
pah cofactor therefor work patient
exist ineffect pah
pivot studi studi kuvan decreas blood phe level
mol/l patient
fulli effect singl agent must use conjunct
low phe diet
use pku patient
pegyl pal phenylalanin ammonia lyas catalyz
phe ammonia tca trans-cinnam acid
approv moder classic pku patient
patient pivot trial develop neutral
blackbox warn first inject administ
supervis healthcar provid equip
manag anaphylaxi administ daili
subcutan inject togeth auto-inject epinephrin
guggenheim secur llc compani file et al genet medicin
page analyst certif import disclosur
